OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)

First Clinical Trial to Test the Safety and Preliminary Activity of Passive Immunotherapy based on a Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. Taipei, Taiwan, January 17, 2018 – OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has […]

This article is password protected.

To view the content, please enter your password in the field below